Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Rosirene Paczkowski"'
Autor:
Jessikah Morales, Namino Glantz, Arianna Larez, Wendy Bevier, Mary Conneely, Ludi Fan, Beverly Reed, Carlos Alatorre, Rosirene Paczkowski, Tamim Ahmed, Andrew Mackenzie, Ian Duncan, David Kerr
Publikováno v:
BMC Endocrine Disorders, Vol 20, Iss 1, Pp 1-13 (2020)
Abstract Background In the United States (U.S.), the prevalence of both diagnosed and undiagnosed type 2 diabetes (T2D) is nearly twice as high among Mexican-origin Hispanic/Latino adults compared to non-Hispanic Whites. Rates of diabetes-related com
Externí odkaz:
https://doaj.org/article/9b2a321559b0418eacc4c5d3aee16dbf
Autor:
Louis S. Matza, Katie D. Stewart, Rosirene Paczkowski, Karin S. Coyne, Brooke Currie, Kristina S. Boye
Publikováno v:
Journal of Patient-Reported Outcomes, Vol 2, Iss 1, Pp 1-12 (2018)
Abstract Background Previous research has examined patient perceptions of insulin injection devices. However, a range of injectable medications other than insulin are now used to treat type 2 diabetes. No patient-reported outcome (PRO) instruments ha
Externí odkaz:
https://doaj.org/article/c3b9bc8ad52247f6a4f8d1c918d34661
Autor:
Louis S. Matza, Kristina S. Boye, Katie D. Stewart, Rosirene Paczkowski, Jessica Jordan, Lindsey T. Murray
Publikováno v:
Journal of Patient-Reported Outcomes, Vol 2, Iss 1, Pp 1-13 (2018)
Abstract Background Previous research has examined patient perceptions of insulin injection devices. However, injectable medications other than insulin are increasingly used to treat type 2 diabetes, including GLP-1 receptor agonists. No patient-repo
Externí odkaz:
https://doaj.org/article/219c426e301841c89e5cc81a56b96450
Publikováno v:
Journal of Patient-Reported Outcomes, Vol 2, Iss 1, Pp 1-14 (2018)
Abstract Objective Nonalcoholic steatohepatitis (NASH) is a form of chronic liver disease (CLD): patients have an increased risk of developing cirrhosis, liver failure, and complications (e.g. hepatocellular carcinoma). NASH has a high clinical burde
Externí odkaz:
https://doaj.org/article/5047face3b2d43fa893d9de3e7f899e5
Publikováno v:
BMC Health Services Research, Vol 17, Iss 1, Pp 1-10 (2017)
Abstract Background Glucagon-like peptide-1 (GLP-1) receptor agonists are often recommended as part of combination therapy for type 2 diabetes when oral medication does not result in sufficient glycemic control. Several GLP-1 receptor agonists are av
Externí odkaz:
https://doaj.org/article/68770f491ec54831bc4cdaddbbc839ad
Autor:
ROSIRENE PACZKOWSKI, MEREDITH HOOG, JENNIFER PELESHOK, MARIA YU, AHONG HUANG, BRENDAN LIMONE, JANNA MANJELIEVSKAIA
Publikováno v:
Diabetes. 71
A retrospective, observational analysis of administrative claims data from the IBM MarketScan Databases assessed adherence and persistence among GLP-1 RA naive adult patients with T2D newly initiating dulaglutide (DU) or oral semaglutide (OS) between
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9e47697d7646a5ae193884df4ecd93fa
https://doi.org/10.2337/db22-92-lb
https://doi.org/10.2337/db22-92-lb
Autor:
Carolina Piras De Oliveira, Rosirene Paczkowski, Jang Ik Cho, Rattan Juneja, Jiat Ling Poon, Emily R Hankosky, Debra A Ignaut, Alfonso Ponce-Ibarra
Publikováno v:
Hand in Hand zum Ziel – einfach.besser.messbar www.diabeteskongress.de.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::895f655dec6ecded8b4440d52ac60b22
https://doi.org/10.1055/s-0042-1746260
https://doi.org/10.1055/s-0042-1746260
Publikováno v:
Advances in therapy. 39(5)
The prevalence of type 2 diabetes (T2D) represents a rising burden in the US and worldwide, with the condition shown to be associated with relatively large human and economic costs. Part of the reason for such high costs associated with T2D is that t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28e1675a300df228e90708d108f3381f
https://pubmed.ncbi.nlm.nih.gov/35316502
https://pubmed.ncbi.nlm.nih.gov/35316502
Autor:
Andrea Goldyn, Rosirene Paczkowski, Carolina Piras De Oliveira, Debra A. Ignaut, Emily R. Hankosky, Jiat Ling Poon, Jang Ik Cho
Publikováno v:
Diabetes. 70
Background: In PRONTO-Pump-2, a Phase 3, 16-week, randomized, double-blind clinical trial in patients with type 1 diabetes on continuous subcutaneous insulin infusion, ultra rapid lispro (URLi) showed superior postprandial glucose control and noninfe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b150a2d74c2480d9fb45f6d40789e504
https://doi.org/10.2337/db21-43-lb
https://doi.org/10.2337/db21-43-lb
Autor:
Debra A. Ignaut, Carolina Piras De Oliveira, Rosirene Paczkowski, Rattan Juneja, Jiat Ling Poon, Jang Ik Cho, Emily R. Hankosky
Publikováno v:
Diabetes. 70
Background: In PRONTO-Pump-2, a Phase 3, 16-week, randomized, double-blind clinical trial in patients with type 1 diabetes on continuous subcutaneous insulin infusion (CSII), ultra rapid lispro (URLi; a novel mealtime insulin), showed superior postpr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5a787612b207828738fd26ad8e11997e
https://doi.org/10.2337/db21-44-lb
https://doi.org/10.2337/db21-44-lb